Development in the syllabus of Pharmaceutical Marketing & Management that is studied in the Bachelor of Pharmacy course of Bangladeshi Universities.        LOSECTIL stands beside acid survivors        Vitamin D Levels Linked to Parkinson's Symptoms        Keeping the newborn warm at home at winter        Itís time to prevent cervical cancer        Huge Rise in CT, MRI, Ultrasound Scan Use: Study        Exercise May Delay Early Aging of People With Diabetes        Alzheimer's Drug Shows Some Promise in Trials        Obesity, Depression Blamed for Daytime Sleepiness Epidemic        Fruits, Veggies May Help Smokers Quit     

Member Sign In
Forgot Your
Username & Password?

Not a Member?
Please Sign Up Here

Sr. Executive / Executive, Production; THE IBN SINA PHARMACEUTICAL IND LTD

Approval of Gralise Extended Release Tablets (gabapentin) by FDA
Brand Name: Gralise Extended Release Tablets
Generic Name: gabapentin
Company Name: Depomed, Inc.
Date of Approval: January 28, 2011
Treatmant for: Postherpetic Neuralgia
Depomed, Inc. today announced that US FDA has approved Gralise (gabapentin) Tablets for once-daily treatment of post-herpetic neuralgia (PHN), which is pain following healing of the rash associated with shingles. Gralise was developed by Depomed under the code name DM-1796 and is licensed to Abbott Products, Inc. in the U.S., Canada and Mexico. The approval of Gralise triggers a milestone payment of $48 million from Abbott to Depomed.

"The approval of Gralise is a major step toward achieving our key strategic objective of sustainable profitability in 2011 and beyond," said Carl Pelzel, President and CEO of Depomed. "I'd like to thank everyone on the Depomed and Abbott teams involved in the development and approval of this important therapy for their hard work and dedication," added Mr. Pelzel.

Michael Sweeney, MD, Vice President of Research and Development for Depomed, noted, "We are delighted with the approval of Gralise, which marks the third FDA approval of a product developed by Depomed. Further, FDA has granted Gralise Orphan Drug status, recognizing Gralise as an important treatment option for patients who suffer from the pain of PHN. We are also very pleased with the product label FDA has approved."

"The Gralise formulation of gabapentin allows for once-a-day dosing and a tolerability profile that will be a positive addition to physicians' treatment armamentarium," said Gordon Irving, MD, Medical Director of the Swedish Pain and Headache Center, Clinical Associate Professor, University of Washington Medical School in Seattle, Washington. "Patients with PHN have long struggled to manage pain following herpes zoster infection. Current therapies require dosing multiple times per day and come with a high incidence of troubling side effects."
Note: To know more please go to the following sources.
Update: 2011-01-31
Source: & FDA
Other FDA Approval
Approval of Sylatron (peginterferon alfa-2b) by FDA
Approval of Viibryd Tablets (vilazodone ) by FDA
Approval of Abstral Sublingual Tablets (fentanyl) by FDA
Approval of Duexis Tablets (famotidine and ibuprofen) by FDA
Approval of Edarbi Tablets (azilsartan medoxomil) by FDA
Approval of Zytiga Tablets (abiraterone) by FDA
Approval of Jakafi (ruxolitinib) by FDA
Approval of Xalkori Capsules (crizotinib) by FDA
See all the FDA Approval